Last updated on February 2019

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry


Brief description of study

Post-marketing safety data on patients treated and untreated with eculizumab.

Detailed Study Description

The study will capture post-marketing safety data on patients treated with eculizumab. Additionally, the study will collect information on the progression of disease in all patients.

Clinical Study Identifier: NCT01522183

Contact Investigators or Research Sites near you

Start Over

CH Perpignan

Perpignan, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.